Insulin human is under clinical development by Diasome Pharmaceuticals and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Insulin human’s likelihood of approval (LoA) and phase transition for Type 2 Diabetes took place on 15 Aug 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 15 Aug 2022 increased Insulin human’s LoA and decreased Phase Transition Success Rate (PTSR) for Type 1 Diabetes (Juvenile Diabetes).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Insulin human Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Insulin human overview

Insulin human (oral HDV-Insulin) is under development for the treatment of type I and type II diabetes. The drug candidate is administered through oral route. Oral HDV-Insulin uses a unique, bionanotechnology based cell targeting system to preferentially deliver insulin to specific sites in the body. It acts by targeting insulin receptor. The drug candidate is developed based on HDV insulin technology. HDV is comprised of proprietary liver-targeting molecules that attach to insulin molecules without changing the structure of the insulin itself.

Diasome Pharmaceuticals overview

Diasome Pharmaceuticals (Diasome) is a pharmaceutical company. It focuses on clinical and commercial development of therapies for diabetes and obesity. The company’s pipeline products include multiple injected and oral formulations of liver targeted insulin’s for both type 1 and type 2 diabetic patients. Diasome’s products include oral HDV insulin, injectable HDV insulin and oral HDV candidates among others. The company’s technology platform Hepatocyte directed vesicle (HDV), a cell targeting system which helps to deliver a wide range of necessary hormones and drugs to the liver. It offers products in the fields of insulin replacement, and hepatic (liver) glucose metabolism. Diasome is headquartered in Cleveland, Ohio, the US.

Quick View Insulin human LOA Data

Report Segments
  • Innovator
Drug Name
  • Insulin human
Administration Pathway
  • Oral
Therapeutic Areas
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.